Published :
Tables : 22
Figures : 40
Category : Healthcare
No. of Pages : 220
Report Code : HC-1296
Active Pharmaceutical Ingredient Market Introduction: Active Pharmaceutical Ingredient Market is estimated to value over USD 253 billion by 2027 end and register a CAGR of over 5.8% during the forecast period 2020 to 2027. An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity. Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market. The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth Going by the product type, the market is divided into innovative and generic APIs. Innovative drugs segment is expected to rise owing to relaxed government rules and regulations. The segment for generic drugs is anticipated to grow in the future because of the affordability and patent expiry of branded drugs. This segment is predicted to expand in the developing nations owing to the untreated medical needs and rapid adoption of over-the-counter drugs. With the type of manufacturer, the market is classified into merchant and captive APIs. Captive API segment holds much strength in the market because of capitalist oriented focus with companies active in the production of availability of raw materials and top-of-the- line manufacturing facilities. With merchant API segment, it is forecasted to be a thriving segment precisely because of a growing need for biopharmaceuticals and exorbitant cost of in-house production of molecules. Moreover, because the captive production of APIs is costly, companies have begun to look to outsourcing to cut back on costs. The biotech type is then categorized recombinant proteins, vaccines and antibodies. Synthetic segment has captured significant market share due to easy accessibility of raw materials, an abundance of revenue shares and relatively easy process of synthesis. Application-wise, the market is broken down into oncology, cardiology, endocrinology and neurology. The cardiology sub-segment has seen a spur in the market because of illnesses such as stroke and heart attack. Some major global players in the APIs market include Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), AbbVie Inc. (US), Pfizer, Inc. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), AstraZeneca plc (UK), Eli Lilly and Company (US). Active Pharmaceutical Ingredient Market Segmentation: By Type Innovative Active Pharmaceutical Ingredients Generic Active Pharmaceutical Ingredients By Type of Manufacturer Captive API Manufacturers Merchant API Manufacturers Merchant Innovative API Manufacturers Merchant Generic API Manufacturers Merchant Synthetic API Manufacturers Merchant Biotech API Manufacturers By Type of Synthesis Synthetic Active Pharmaceutical Ingredients Innovative Synthetic APIS Generic Synthetic APIS Biotech Active Pharmaceutical Ingredients Innovative biotech APIs Generic biotech APIs By Product Monoclonal Antibodies Hormones & Growth Factors Cytokines Fusion Proteins Recombinant Vaccines Therapeutic Enzymes Blood Factors By Type of Drug Prescription Drugs Over-The-Counter Drugs By Potency Low-To-Moderate Potency Active Pharmaceutical Ingredients Potent-To-Highly Potent Active Pharmaceutical Ingredients By Therapeutic Application Communicable Diseases Oncology Pain Management Cardiovascular Diseases Diabetes Respiratory Diseases Other Therapeutic Applications By Region North America Europe Asia- Pacific Rest Of World FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the active pharmaceuticals market by type, by manufacturer, by type of synthesis, by product, by type of drug, by potency, by therapeutic application and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities) To forecast and evaluate micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the rest of the world To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Active Pharmaceutical Ingredient Market is estimated to value over USD 253 billion by 2027 end and register a CAGR of over 5.8% during the forecast period 2020 to 2027.
An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity.
Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market.
The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth
Going by the product type, the market is divided into innovative and generic APIs. Innovative drugs segment is expected to rise owing to relaxed government rules and regulations. The segment for generic drugs is anticipated to grow in the future because of the affordability and patent expiry of branded drugs. This segment is predicted to expand in the developing nations owing to the untreated medical needs and rapid adoption of over-the-counter drugs.
With the type of manufacturer, the market is classified into merchant and captive APIs.
Captive API segment holds much strength in the market because of capitalist oriented focus with companies active in the production of availability of raw materials and top-of-the- line manufacturing facilities. With merchant API segment, it is forecasted to be a thriving segment precisely because of a growing need for biopharmaceuticals and exorbitant cost of in-house production of molecules. Moreover, because the captive production of APIs is costly, companies have begun to look to outsourcing to cut back on costs.
The biotech type is then categorized recombinant proteins, vaccines and antibodies. Synthetic segment has captured significant market share due to easy accessibility of raw materials, an abundance of revenue shares and relatively easy process of synthesis. Application-wise, the market is broken down into oncology, cardiology, endocrinology and neurology. The cardiology sub-segment has seen a spur in the market because of illnesses such as stroke and heart attack.
Some major global players in the APIs market include Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), AbbVie Inc. (US), Pfizer, Inc. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), AstraZeneca plc (UK), Eli Lilly and Company (US).
Active Pharmaceutical Ingredient Market Segmentation:
By Type
By Type of Manufacturer
By Type of Synthesis
By Product
By Type of Drug
By Potency
By Therapeutic Application
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Active Pharmaceutical Ingredient Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Active Pharmaceutical Ingredient Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Active Pharmaceutical Ingredient Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Active Pharmaceutical Ingredient Market , By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Innovative Active Pharmaceutical Ingredients 7.2. Generic Active Pharmaceutical Ingredients 8. Global Active Pharmaceutical Ingredient Market , By Type of Manufacturer Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Captive API Manufacturers 8.2. Merchant API Manufacturers 8.2.1. Merchant Innovative API Manufacturers 8.2.2. Merchant Generic API Manufacturers 8.2.3. Merchant Synthetic API Manufacturers 8.2.4. Merchant Biotech API Manufacturers 9. Global Active Pharmaceutical Ingredient Market , By Type of Synthesis Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Synthetic Active Pharmaceutical Ingredients 9.1.1. Innovative Synthetic APIS 9.1.2. Generic Synthetic APIS 9.2. Biotech Active Pharmaceutical Ingredients 9.2.1. Innovative biotech APIs 9.2.2. Generic biotech APIs 10. Global Active Pharmaceutical Ingredient Market , By Product Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Monoclonal Antibodies 10.2. Hormones & Growth Factors 10.3. Cytokines 10.4. Fusion Proteins 10.5. Recombinant Vaccines 10.5.1. Therapeutic Enzymes 10.5.2. Blood Factors 11. Global Active Pharmaceutical Ingredient Market, By Type of Drug Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Prescription Drugs 11.2. Over-The-Counter Drugs 12. Global Active Pharmaceutical Ingredient Market , By Potency Historical Analysis and Forecast 2020-2027 (USD Million) 12.1. Low-To-Moderate Potency Active Pharmaceutical Ingredients 12.2. Potent-To-Highly Potent Active Pharmaceutical Ingredients 13. Global Active Pharmaceutical Ingredient Market , By Therapeutic Application Historical Analysis and Forecast 2020-2027 (USD Million) 13.1. Communicable Diseases 13.2. Oncology 13.3. Pain Management 13.4. Cardiovascular Diseases 13.5. Diabetes 13.6. Respiratory Diseases 13.7. Other Therapeutic Applications 14. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. U.S.A 14.2.2. Canada 14.2.3. Mexico 14.3. Market Size (USD Million) Forecast for North America 2020-2027 15. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Brazil 15.2.2. Venezuela 15.2.3. Argentina 15.2.4. Rest of Latin America 15.3. Market Size (USD Million) Forecast for Latin America 2020-2027 16. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 16.2.1. Germany 16.2.2. U.K 16.2.3. France 16.2.4. Italy 16.2.5. Spain 16.2.6. Russia 16.2.7. Poland 16.2.8. Switzerland 16.2.9. Rest of Western Europe 17. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 17.2.1. Japan 17.2.2. China 17.2.3. Singapore 17.2.4. India 17.2.5. Australia and New Zealand 17.2.6. ASEAN 17.2.7. South Korea 17.2.8. Rest of Asia Pacific 17.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 18. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 18.1. Introduction 18.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 18.2.1. Saudi Arabia 18.2.2. UAE 18.2.3. South Africa 18.2.4. Egypt 18.3. Market Size (USD Million) Forecast for MEA 2020-2027 19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 19.1. Sanofi (France) 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2. Teva Pharmaceutical Industries Ltd. (Israel) 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. AbbVie Inc. (US) 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Pfizer, Inc. (US) 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Boehringer Ingelheim (Germany) 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. F. Hoffmann-La Roche Ltd. (Switzerland) 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. GlaxoSmithKline plc (UK) 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Novartis AG (Switzerland) 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. Merck & Co., Inc. (US) 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10. Bristol-Myers Squibb (US) 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11. AstraZeneca plc (UK) 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12. Eli Lilly and Company (US) 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 20. FutureWise SME key takeaway points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Active Pharmaceutical Ingredient Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Active Pharmaceutical Ingredient Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Active Pharmaceutical Ingredient Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Active Pharmaceutical Ingredient Market , By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Innovative Active Pharmaceutical Ingredients 7.2. Generic Active Pharmaceutical Ingredients 8. Global Active Pharmaceutical Ingredient Market , By Type of Manufacturer Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Captive API Manufacturers 8.2. Merchant API Manufacturers 8.2.1. Merchant Innovative API Manufacturers 8.2.2. Merchant Generic API Manufacturers 8.2.3. Merchant Synthetic API Manufacturers 8.2.4. Merchant Biotech API Manufacturers 9. Global Active Pharmaceutical Ingredient Market , By Type of Synthesis Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Synthetic Active Pharmaceutical Ingredients 9.1.1. Innovative Synthetic APIS 9.1.2. Generic Synthetic APIS 9.2. Biotech Active Pharmaceutical Ingredients 9.2.1. Innovative biotech APIs 9.2.2. Generic biotech APIs 10. Global Active Pharmaceutical Ingredient Market , By Product Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Monoclonal Antibodies 10.2. Hormones & Growth Factors 10.3. Cytokines 10.4. Fusion Proteins 10.5. Recombinant Vaccines 10.5.1. Therapeutic Enzymes 10.5.2. Blood Factors 11. Global Active Pharmaceutical Ingredient Market, By Type of Drug Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Prescription Drugs 11.2. Over-The-Counter Drugs 12. Global Active Pharmaceutical Ingredient Market , By Potency Historical Analysis and Forecast 2020-2027 (USD Million) 12.1. Low-To-Moderate Potency Active Pharmaceutical Ingredients 12.2. Potent-To-Highly Potent Active Pharmaceutical Ingredients 13. Global Active Pharmaceutical Ingredient Market , By Therapeutic Application Historical Analysis and Forecast 2020-2027 (USD Million) 13.1. Communicable Diseases 13.2. Oncology 13.3. Pain Management 13.4. Cardiovascular Diseases 13.5. Diabetes 13.6. Respiratory Diseases 13.7. Other Therapeutic Applications
14. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. U.S.A 14.2.2. Canada 14.2.3. Mexico 14.3. Market Size (USD Million) Forecast for North America 2020-2027 15. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Brazil 15.2.2. Venezuela 15.2.3. Argentina 15.2.4. Rest of Latin America 15.3. Market Size (USD Million) Forecast for Latin America 2020-2027 16. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 16.2.1. Germany 16.2.2. U.K 16.2.3. France 16.2.4. Italy 16.2.5. Spain 16.2.6. Russia 16.2.7. Poland 16.2.8. Switzerland 16.2.9. Rest of Western Europe 17. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 17.2.1. Japan 17.2.2. China 17.2.3. Singapore 17.2.4. India 17.2.5. Australia and New Zealand 17.2.6. ASEAN 17.2.7. South Korea 17.2.8. Rest of Asia Pacific 17.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 18. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 18.1. Introduction 18.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 18.2.1. Saudi Arabia 18.2.2. UAE 18.2.3. South Africa 18.2.4. Egypt 18.3. Market Size (USD Million) Forecast for MEA 2020-2027
19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 19.1. Sanofi (France) 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2. Teva Pharmaceutical Industries Ltd. (Israel) 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. AbbVie Inc. (US) 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Pfizer, Inc. (US) 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Boehringer Ingelheim (Germany) 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. F. Hoffmann-La Roche Ltd. (Switzerland) 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. GlaxoSmithKline plc (UK) 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Novartis AG (Switzerland) 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. Merck & Co., Inc. (US) 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10. Bristol-Myers Squibb (US) 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11. AstraZeneca plc (UK) 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12. Eli Lilly and Company (US) 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 20. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics